Among the peptides reaching UAE research laboratories — from Business Bay biotech operations to pharmacology departments in Abu Dhabi — two compounds have generated sustained, evidence-grounded interest: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) and MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c). On the surface they look unrelated. GHK-Cu is a copper-binding tripeptide with a decades-long peer-reviewed history, studied for its effects on tissue remodelling and broad-spectrum gene expression modulation. MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, characterised relatively recently for its metabolic signalling properties.
What makes them an intellectually compelling research pair is precisely that divergence: they appear to operate on separate but potentially upstream-connected cellular axes. GHK-Cu works at the level of nuclear gene transcription, modulating a remarkably wide range of pathways as documented by Pickart (2018) and Campbell et al. (2012). MOTS-c transmits signals from the mitochondria back to the nucleus, influencing metabolic homeostasis through a distinct route described by Lee et al. (2015). Stacking them is not about redundancy — it is about probing two related but non-overlapping mechanisms within a single structured research protocol. UAE labs running this combination are asking a mechanistically motivated question, and that is exactly the kind of work worth doing carefully.
This article is written strictly for research context. Nothing here constitutes medical advice, clinical guidance, or a therapeutic recommendation. All compounds discussed are for in-laboratory research use only. For researchers in Dubai or elsewhere in the UAE ready to source GHK-Cu, REVIVE LAB UAE stocks both 50mg and 100mg vials with same-day Dubai dispatch — ordering details below. First, the science.
GHK-Cu has one of the longer peer-reviewed histories of any research peptide currently in active circulation. The compound was identified in human plasma decades ago, and subsequent research built a detailed mechanistic picture. The tripeptide's binding affinity for copper (II) ions gives it a distinctive biochemical profile: it acts as a copper chaperone, and the Cu(II) complex appears to be responsible for much of its biological activity in research models.
Pickart's 2018 review in Cosmetics remains the most comprehensive synthesis of GHK-Cu's documented effects on gene expression. The review catalogues GHK-Cu's capacity to upregulate genes associated with collagen synthesis, anti-inflammatory signalling, and antioxidant defence — while simultaneously downregulating genes associated with inflammatory cascades and tissue degradation. The gene expression footprint described in that literature is notably broad: analysis drew on data showing GHK-Cu influencing the expression of thousands of human genes, positioning it as a pleiotropic signalling molecule rather than a single-pathway compound. That breadth is both its scientific interest and a reason to design controlled research protocols carefully.
Campbell et al. (2012) in BMC Genomics provided important mechanistic depth, profiling gene expression changes triggered by GHK across multiple cellular pathways. Their work identified modulation of networks relevant to tissue remodelling, antioxidant function, and mitochondrial gene regulation — that last detail being where the MOTS-c connection becomes most interesting for researchers designing combinatorial protocols. If GHK-Cu demonstrably touches mitochondrial gene networks at the transcriptional level, and MOTS-c acts as a mitochondria-derived retrograde signal, the two compounds are not operating in completely separate compartments.
In published research contexts, GHK-Cu has been studied via two primary administration routes: topical application and subcutaneous (SC) injection. Literature-cited research-context ranges for SC delivery run between 1 mg and 3 mg per day. Topical formulations vary by carrier vehicle, but the tripeptide's low molecular weight (approximately 340 Da) supports transdermal penetration in appropriate formulations. Researchers designing SC protocols should note that GHK-Cu is water-soluble and reconstitutes readily.
REVIVE LAB UAE supplies GHK-Cu as a lyophilised powder in 50mg and 100mg research vials. The 50mg vial is well suited for shorter research runs, pilot phases, or multi-subject studies where each subject requires a modest total volume. The 100mg vial offers meaningfully better per-milligram value for extended protocols or for labs running parallel experimental arms simultaneously and wanting to avoid mid-protocol reorder gaps.
| Parameter | GHK-Cu — Research Context |
|---|---|
| Vial sizes (REVIVE LAB UAE) | 50mg, 100mg (lyophilised) |
| SC range cited in literature | 1–3 mg/day |
| Administration routes in published studies | Topical, subcutaneous |
| Reconstitution solvent (common) | Bacteriostatic water |
| Post-reconstitution stability (refrigerated) | Up to 4 weeks at 2–8°C per standard peptide handling guidance |
| In-stock UAE | Yes — same-day dispatch Dubai, 24h UAE-wide |
| Key citations | Pickart 2018 (Cosmetics); Campbell et al. 2012 (BMC Genomics) |
MOTS-c was formally characterised by Lee et al. in their 2015 paper in Cell Metabolism — a landmark publication that identified it as a bioactive peptide encoded within the 12S rRNA region of mitochondrial DNA. That genomic location had not previously been recognised as a coding sequence for a functional peptide, which made the discovery significant for both mitochondrial biology and metabolic research.
What Lee and colleagues demonstrated in their preclinical research models was that MOTS-c promotes metabolic homeostasis and attenuates insulin resistance and obesity-associated fat accumulation under high-fat dietary conditions. The mechanistic pathway they proposed involves MOTS-c translocating from the mitochondria to the nucleus — a form of mitochondria-to-nucleus retrograde signalling — where it regulates nuclear gene expression directly. In metabolic terms, the published data implicated AMPK pathway activation and enhanced glucose utilisation in skeletal muscle as key downstream effects. This immediately distinguished MOTS-c from the GLP-1 class of metabolic peptides with which researchers working in the UAE GLP-1 space will be familiar.
It is important to be clear about where MOTS-c research currently sits: the bulk of published data comes from preclinical models. The Lee et al. 2015 paper remains the foundational primary citation, and while subsequent work has elaborated on MOTS-c's signalling properties, researchers designing human-adjacent protocols should treat the compound as early-phase investigation material. REVIVE LAB UAE does not publish dose recommendations for MOTS-c. Researchers should derive their protocol parameters directly from the primary literature — Lee et al. (2015) in Cell Metabolism is the appropriate starting point — and should not rely on supplier content for dose parameters. Contact REVIVE LAB UAE via WhatsApp for current stock availability and format options.
The research case for combining GHK-Cu and MOTS-c rests on the observation that they operate on different but potentially interacting upstream processes. A useful framing is to think of GHK-Cu as operating primarily at the level of transcriptional modulation via nuclear gene expression — with a documented reach into mitochondrial gene networks (Campbell et al. 2012) — while MOTS-c operates as a mitochondria-originating signal that travels upstream to the nucleus to regulate metabolic gene expression (Lee et al. 2015). The directionality is different. The final destination — nuclear gene regulation with metabolic and regenerative downstream effects — overlaps.
The working hypothesis that makes this stack interesting: if GHK-Cu's transcriptional effects include mitochondrial gene network modulation, and MOTS-c's activity depends on mitochondria-to-nucleus communication, then co-administration might create conditions where both pathways are simultaneously active, allowing researchers to observe interaction effects they would not see in single-compound protocols. This is not a claim of synergy in any clinical sense — that would require controlled trial data that does not exist. It is a mechanistically grounded reason to investigate the combination rather than run each compound in isolation.
To be equally clear about what the combination does not represent: this is not a protocol designed for a specific therapeutic outcome. Researchers in Dubai labs who have come to this stack via anecdotal or supplement-market channels should approach it with the same controlled, hypothesis-driven methodology they would apply to any preclinical combinatorial work. The value is in the research question being asked, not in a predetermined result. REVIVE LAB UAE's role is to supply research-grade compounds; the protocol design and interpretation sits entirely with the research institution.
GHK-Cu — In Stock at REVIVE LAB UAE
50mg and 100mg lyophilised research vials. Same-day dispatch in Dubai. 24h delivery across the UAE. Discreet packaging. Cash on delivery available in Dubai. MOTS-c stocked alongside.
Buy GHK-Cu UAE — Same-Day Dubai Dispatch from REVIVE LAB UAEThe following is a research-context framework only. No medical advice is implied or intended. Researchers should design protocols in line with their institution's ethics requirements and applicable UAE regulations, and should anchor all dose parameters in the primary peer-reviewed literature.
Published research models have used GHK-Cu in the 1–3 mg/day range for subcutaneous delivery. For a 30-day research run using a 1 mg/day SC protocol, a single 50mg vial from REVIVE LAB UAE provides substantial headroom for a multi-subject pilot design or for sequential single-subject phases with material to spare. The 100mg vial makes operational sense for extended protocols running beyond 30 days at higher per-day volumes, or where parallel experimental arms are running simultaneously and mid-study reorder risk should be avoided. Both sizes are in stock and can be dispatched the same day to Dubai addresses including Jumeirah, JBR, the Marina, Business Bay, DIFC, Downtown, and the Palm.
Reconstitution is typically performed with bacteriostatic water for multi-day use, as the benzyl alcohol preservative extends vial stability post-reconstitution. Sterile water for injection is appropriate for same-day use only. Concentration should be calculated per the specific protocol requirements — document the target volume per draw, confirm vial contents by weight, and reconstitute to the concentration that gives the target volume with a standard insulin syringe. Label every reconstituted vial with concentration and date before storing.
Researchers should consult Lee et al. (2015) in Cell Metabolism as the foundational reference for preclinical MOTS-c protocol design. Specific dose parameters for MOTS-c are deliberately omitted from this article: the research landscape for MOTS-c is at an earlier stage than GHK-Cu, the published data is primarily preclinical, and it is not REVIVE LAB UAE's position to serve as a dosing reference for a compound where the human data is this limited. What can be said is that MOTS-c is a small peptide (16 amino acids, MW approximately 2.1 kDa), reconstitutes cleanly, and should be handled with the same cold-chain care as GHK-Cu. Contact REVIVE LAB UAE via WhatsApp for format options and current availability.
Researchers designing a GHK-Cu / MOTS-c combinatorial study face an early choice between concurrent administration and sequential phasing. Each has a defensible rationale:
| Protocol Variable | Concurrent Design | Sequential (Crossover) Design |
|---|---|---|
| Interaction effects observable | Yes | No (by design) |
| Attribution of individual effects | Confounded | Cleanly separated |
| Mechanistic hypothesis testable | Interaction hypothesis | Individual compound characterisation |
| GHK-Cu quantity required | Both compounds at once (100mg vial recommended) | Staggered; can reorder between phases (50mg per phase) |
| Washout period needed | Not applicable | Recommended between arms |
| Best suited for | Interaction / combined effect hypothesis | Baseline characterisation of each compound independently |
If your lab is new to either compound, the sequential design is the more defensible starting point: run GHK-Cu in isolation, document what you observe, then introduce MOTS-c in a subsequent phase. That approach builds internal reference data and makes any combined-arm findings more interpretable. For labs already working with one compound and adding the other, concurrent design makes sense if the research question is specifically about the interaction.
Researchers ordering research peptides into the UAE face a set of practical challenges that researchers in temperate climates do not. In June 2026, ambient temperatures across Dubai, Abu Dhabi, Sharjah, and the Northern Emirates regularly exceed 40°C. Sharjah industrial zones, Abu Dhabi research campuses, and even well-managed Dubai lab spaces face temperature spikes that make peptide stability a genuine variable — not a theoretical one.
Lyophilised (freeze-dried) peptide vials are substantially more thermally stable than reconstituted solutions. In lyophilised form, GHK-Cu and MOTS-c can tolerate short transient excursions above ideal storage temperature during transit without meaningful degradation — particularly when shipped with cold-pack insulation, which REVIVE LAB UAE includes for all orders. Once reconstituted, the stability window narrows significantly: reconstituted GHK-Cu should be stored at 2–8°C and used within the protocol timeframe. Freeze-thaw cycles post-reconstitution should be avoided.
This is a concrete, practical advantage of sourcing GHK-Cu domestically in the UAE. An order placed with a European or US supplier travels through ambient cargo holds, customs warehousing at DXB or Abu Dhabi Airport (where dwell time is variable), and last-mile delivery vans operating in 42°C summer heat. That is a cold chain that is structurally difficult to guarantee end-to-end. REVIVE LAB UAE holds stock in-country and dispatches with cold-pack insulation to Dubai addresses on the same day, and to Sharjah, Abu Dhabi, Ajman, Fujairah, and Ras Al Khaimah within 24 hours.
International peptide orders arriving at DXB or Abu Dhabi Airport encounter variable customs clearance timelines. Even routine shipments can face 5–10 business day delays during inspection periods, and research timelines rarely have that buffer built in. Researchers at labs in JBR, on the Palm, in Business Bay, or at Abu Dhabi university campuses have encountered this friction point and understand its cost in both time and experimental continuity. REVIVE LAB UAE was established precisely to eliminate that friction: all stock is held in-country, there is no customs exposure, and same-day dispatch to Dubai is available. For time-sensitive protocols, the domestic sourcing advantage is not marginal — it is decisive.
A practical note on reconstitution, given the UAE climate's specific demands on in-lab handling:
The UAE research peptide supply landscape has developed considerably in the past two years, and the quality and logistics variance between suppliers has become a more pressing concern as protocols become more sophisticated. Researchers who have experienced degraded product, opaque sourcing, or delivery failures mid-protocol have largely migrated toward domestic suppliers with transparent stock visibility and logistics that are designed for UAE conditions specifically. REVIVE LAB UAE has built its position in that space through in-country stock depth, UAE-appropriate cold-chain logistics, and ordering mechanics that reflect how UAE researchers actually want to transact.
All sales are to verified research accounts. REVIVE LAB UAE does not sell to the general public and does not supply compounds for human or veterinary consumption. Researchers in the UAE who have not yet established an account can initiate one via the GHK-Cu product page or directly via WhatsApp.
Yes. REVIVE LAB UAE stocks GHK-Cu in 50mg and 100mg research vials held in-country and offers same-day dispatch within Dubai for orders placed before the daily cutoff. 24-hour delivery is available across the wider UAE including Abu Dhabi, Sharjah, Ajman, Fujairah, and Ras Al Khaimah. Cash on delivery is available for Dubai deliveries. All orders ship in discreet, temperature-controlled packaging with no product details on the outer label.
REVIVE LAB UAE stocks GHK-Cu in 50mg and 100mg lyophilised research vials. Both sizes are held in-country in the UAE, eliminating the customs delays and cold-chain degradation risks that come with ordering from European or US suppliers into DXB or Abu Dhabi Airport. The 50mg vial suits pilot studies and shorter protocol runs; the 100mg vial offers better per-milligram value for extended protocols or multi-arm study designs.
Yes. REVIVE LAB UAE offers cash on delivery for GHK-Cu orders within Dubai — no additional fee. Alternatively, payment via Binance Pay (USDT TRC20) earns a 5% pre-pay discount, with WhatsApp txid confirmation handling the settlement. Both methods are available for same-day Dubai dispatch. All orders ship in discreet outer packaging regardless of payment method.
Order GHK-Cu UAE — REVIVE LAB UAE
50mg and 100mg lyophilised research vials. In stock today. Same-day dispatch in Dubai. 24h delivery across the UAE. Discreet packaging. Cash on delivery available. MOTS-c stocked alongside.
Buy GHK-Cu UAE — Order Now from REVIVE LAB UAE